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We identified three retinoid-related orphan receptor
gamma t (RORgt)-specific inhibitors that suppress
T helper 17 (Th17) cell responses, including Th17-
cell-mediated autoimmune disease. We systemically
characterized RORgt binding in the presence and
absence of drugs with correspondingwhole-genome
transcriptome sequencing. RORgt acts as a direct
activator of Th17 cell signature genes and a direct
repressor of signature genes from other T cell line-
ages; its strongest transcriptional effects are on
cis-regulatory sites containing the RORa binding
motif. RORgt is central in a densely interconnected
regulatory network that shapes the balance of T cell
differentiation. Here, the three inhibitors modulated
the RORgt-dependent transcriptional network to
varying extents and through distinct mechanisms.
Whereas one inhibitor displaced RORgt from its
target loci, the other two inhibitors affected tran-
scription predominantly without removing DNA bind-
ing. Our work illustrates the power of a system-scale
analysis of transcriptional regulation to characterize
potential therapeutic compounds that inhibit patho-
genic Th17 cells and suppress autoimmunity.
INTRODUCTION
T helper 17 (Th17) cells, induced by the ‘‘master’’ transcription
factor (TF) retinoid-related orphan receptor gamma t (RORgt),play an important role in chronic inflammation and autoimmune
diseases (Korn et al., 2009). The central role of Th17 cells
in human autoimmune diseases has been highlighted by
genome-wide association studies that have linked genes prefer-
entially expressed in Th17 cells, including STAT3 and IL23R, to
multiple human autoimmune diseases, including psoriasis,
inflammatory bowel disease, and ankylosing spondylitis (Cho,
2008; Lees et al., 2011; Nair et al., 2009; Reveille et al., 2010;
Zhang et al., 2012). Recent success in clinical trials for the treat-
ment of psoriasis and rheumatoid arthritis with biologics that
inhibit the Th17 cell pathway (ixekizumab and brodalumab)
further underscores the importance of this pathway in human
autoimmunity (Genovese et al., 2010; Leonardi et al., 2012;
Papp et al., 2012). Although blockade of interleukin-17A
(IL-17A) alone with secukinumab, an IL-17A monoclonal anti-
body, proved ineffective in Crohn’s disease patients and might
paradoxically worsen disease in a subset of patients (Hueber
et al., 2012), secukinumab has demonstrated potential for
treatment of other autoimmune conditions, including psoriasis
and ankylosing spondylitis (Patel et al., 2013), suggesting
variability in response among diseases.
Each of several closely related but highly functionally special-
ized CD4+ T helper cell populations enacts a distinct regulatory
program, allowing for their diverse effector functions in the
immune response. Accordingly, so-called ‘‘master’’ regulator
TFs that are selectively expressed in each cell population and
are required for their proper development and function have
been identified. RORgt, themaster TF of Th17 cells, is selectively
expressed in Th17 cells, promotes Th17 cell differentiation,
and is essential for the development of Th17 cells (Ivanov
et al., 2006). Genomic studies have revealed transcriptional
targets of key regulatory factors in other CD4+ T cell populations,
including Foxp3 in regulatory T (Treg) cells (Birzele et al., 2011;Immunity 40, 477–489, April 17, 2014 ª2014 Elsevier Inc. 477
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andGATA3 in Th2 cells (Jenner et al., 2009;Wei et al., 2011; Kan-
here et al., 2012). A systematic understanding of the genomic
targets of RORgt and the transcriptional network that controls
differentiation of Th17 cells is beginning to emerge (Ciofani
et al., 2012; Yosef et al., 2013) and provides a unique opportunity
to instruct the development of small-molecular-weight com-
pounds that selectively suppress pathogenic effector functions
of Th17 cells.
RORgt is an attractive pharmacologic target for the treatment
of Th17-cell-mediated immune disorders because it plays a
central role in Th17 cell function and is a nuclear receptor with
a ligand-binding pocket. Indeed, several small-molecular-weight
compounds that can inhibit the function of RORgt, including
digoxin (Huh et al., 2011) and SR1001 (Solt et al., 2011), have
been identified. Although these molecules inhibit transcription
of some genes that are preferentially expressed in Th17 cells,
the direct transcriptional effects of RORgt inhibitors have not
been analyzed, and no comprehensive examination of the
effects of the molecules on RORgt targets and its transcriptional
network has been possible.
Here, we report the identification of three small-molecule
RORgt inhibitors that potently hinder the development of Th17
cells and the severity of experimental autoimmune encephalo-
myelitis (EAE), a murine model of multiple sclerosis. To dissect
the molecular mechanism underlying the effect of these com-
pounds, we characterized the direct transcriptional targets of
RORgt and report here the transcriptional effects of the three
small molecules, as well as digoxin, on gene expression and
on RORgt occupancy of its genomic targets. Remarkably,
whereas one compound disrupted RORgt binding to genomic
DNA, the other two compounds affected transcriptional regula-
tion without globally eliminating RORgt DNA binding. This
suggests that compounds can effectively disrupt the RORgt-
dependent transcriptional program in Th17 cells either by dis-
placing RORgt or by altering its transcriptional effects without
affecting DNA binding. These studies show the power of using
genomic data to guide selection of drug candidates that can
selectively inhibit functions of pathogenic Th17 cells and sup-
press autoimmunity.
RESULTS
Screening for Selective RORgt Inverse Agonists
Using a fluorescence resonance energy transfer (FRET) assay,
consisting of the RORgt ligand-binding domain and cofactor
peptide SRC1, we screened a proprietary small-molecule library
and identified several compounds that bind to RORgt (Supple-
mental Experimental Procedures, available online). Of particular
interest was a scaffold with a benzhydryl amide group, which
was selected for further chemistry optimization. Extensive struc-
ture-activity-relationship studies on the scaffold led to the iden-
tification of TMP778 and TMP920 as highly potent and selective
RORgt inhibitors (Figure 1A). Both molecules share a benzhydryl
amide moiety and an electron-rich heterocycle (isoxazole).
TMP778 possesses a rigid benzofuran ring in the central portion
of the molecule, whereas TMP920 manifests higher flexibility in
that region with its aryl ether moiety. TMP778 and TMP920
inhibited RORgt binding to SRC1 in the FRET assay with a half478 Immunity 40, 477–489, April 17, 2014 ª2014 Elsevier Inc.maximal inhibitory concentration (IC50) of 0.005 and 0.03 mM,
respectively (Figures S1A and S1B).
We initially confirmed the activity and selectivity of these
putative RORgt inhibitors in vitro with a cell-based nuclear
receptor reporter assay (Supplemental Experimental Proce-
dures). Both compounds potently inhibited RORgt-dependent
transactivation. Dose response curves for luciferase activity
revealed that the IC50 of TMP778 was 0.017 mM in RORg assays.
By comparison, the IC50 was roughly 100-fold higher for RORa
and RORb (1.24 and 1.39 mM, respectively; Figure S1C). The
IC50 for TMP920 in RORg assays was 1.1 mm (Figure S1D).
Further highlighting the selective effect of these compounds on
RORgt, the IC50 for both TMP778 and TMP920 was greater
than 10 mM in luciferase assays for 22 other nuclear receptors
(Figure S1E). These results indicate that TMP778 and TMP920,
identified through the FRET assay, are selective and potent
RORgt inhibitors.
RORgt Inhibitors Suppress Th17 Cell Differentiation
In Vitro
To determine whether RORgt inhibitors affect Th17 cell differen-
tiation in vitro, we cultured primary naive CD4+ T cells under
Th17-cell-polarizing conditions in the presence of different
doses of TMP778, TMP920, digoxin, or DMSO (vehicle control).
We first measured the effect of the inhibitors on cell proliferation.
TMP778 at >2.5 mM and TMP920 and digoxin at >10 mM started
to show toxic effects on cell growth, which, however, was not
RORgt-dependent, given that the proliferation of RORgt-defi-
cient T cells (Rorc/ cells from CD4-Cre+Rorcfl/fl mice, which
specifically do not express RORg or RORgt in CD4+ T cells)
cultured under Th17-cell-polarizing conditions was also
decreased (Figure S1F). Otherwise, these inhibitors did not
show inhibitory effects on cell proliferation or RORgt expression
or its nuclear translocation (RORgt expression was increased by
some compounds, such as TMP920; Figures S1F and S1G) but
efficiently inhibited IL-17 production. As reported previously,
digoxin, one of the first-identified RORgt inhibitors (Huh et al.,
2011), specifically inhibited IL-17 production in Th17 cell cultures
at 10 mM; however, at <2.5 mM, its inhibitory effect on IL-17 pro-
duction was lost. Similarly, TMP920 lost its IL-17 inhibitory effect
at <2.5 mM; however, TMP778 had a much broader dose range
and efficiently decreased IL-17 production (Figure S1F), consis-
tent with its higher binding affinity for RORgt. These data indicate
that TMP778, followed by TMP920 and digoxin, is the RORgt
inhibitor that most potently reduced IL-17 production. On
the basis of the dose-response curves, we chose 2.5 mM of
TMP778 and 10 mM of TMP920 and digoxin for subsequent
in vitro experiments because at these concentrations, the
respective RORgt inhibitors were not toxic to the cells but
maximally inhibited the generation of Th17 cells (Figures 1B
and S1F).
RORgt Inhibitors Suppress IL-17 Production from
Differentiated Th17 Cells In Vitro
We next asked whether TMP778 and TMP920 also inhibit IL-17
production from differentiated Th17 cells. Draining lymph node
cells from wild-type (WT) and RORgt-deficient mice immunized
with MOG35–55 plus complete Freund’s adjuvant (CFA) for the
development of EAE were restimulated with MOG35–55 in the
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Figure 1. RORgt Inhibitors Suppress Th17 Cell Differentiation and Maintenance and Ameliorate EAE
(A) Chemical structures of TMP778, TMP920, and digoxin.
(B) Naive CD4+ T cells were activated with anti-CD3 and anti-CD28 under Th17-cell-polarizing conditions in the presence of optimal doses (not toxic but with
maximal IL-17 inhibition) of TMP778 (2.5 mM), TMP920 (10 mM), digoxin (10 mM), or DMSO. After 4 days, IL-17 and interferon-g (IFN-g) production was measured
by intracellular cytokine staining. Data are representative of five to eight experiments.
(C) Draining lymph node cells from mice immunized with MOG35–55 plus CFA for the development of EAE were restimulated with MOG35–55 in the presence of
IL-23 plus TMP778, TMP920, digoxin, or DMSO. After 4 days, production of IL-17 and IFN-g in CD4+ T cells was determined by intracellular cytokine staining. The
left panel shows representative fluorescence-activated-cell-sorting plots of the frequencies of IFN-g- and IL17-producing cells in gated CD4+ T cells from
samples treated with DMSO and TMP778; the right panel shows the statistical data (n = 5). Error bars represent the mean ± SD. *p < 0.01.
(D) C57BL/6 mice were immunized with MOG35–55 plus CFA, and RORgt inhibitor (TMP778, 200 mg per injection, n = 19; TMP920, 500 mg per injection, n = 7;
digoxin, 50 mg per injection, n = 5 [>100 mg caused mouse death]; DMSO, n = 19) was subcutaneously injected twice daily starting from day 0. Mice were
evaluated daily for signs of EAE. Error bars represent themean ± SD. Eleven days later, groups ofmice treatedwith different RORgt inhibitors were comparedwith
the group of mice with DMSO (vehicle control) treatment (*p < 0.05).
(E) CNS-infiltrating mononuclear cells were isolated from brains and spinal cords of the mice on day 21 after EAE induction. IL-17 and IFN-g production of CNS-
infiltrating CD4+ T cells was determined by intracellular staining. Data are representative of four to five mice in each group.
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RORgt Inhibitors Regulate Th17 Cell Transcriptomepresence of IL-23 and with the different RORgt inhibitors, and
cytokine production in CD4+ T cells was measured by intra-
cellular cytokine staining. Compared to WT T cells, RORgt-defi-
cient CD4+ T cells showed much lower frequencies of IL-17+
cells but increased frequencies of interferon-g (IFN-g)+IL-17
populations. All compounds inhibited IL-17 production (both
IFN-gIL-17+and IFN-g+IL-17+ T cells were reduced) to different
degrees in WT, but not RORgt-deficient, CD4+ T cells, and
TMP778 demonstrated the most potent inhibition (Figure 1C).
None of the compounds altered the frequencies of IFN-g+
IL-17 T cells in either WT or RORgt-deficient mice (Figure 1C).
Also, all compounds increased frequencies of IL-2+ cells inIL-17+ T cells (Figure S1H). These data suggest that the RORgt
inhibitors inhibit Th17 cell responses not only by reducing IL-17
production but also by blocking the decrease in IL-2 production
that normally occurs as Th17 cells differentiate (McGeachy et al.,
2009).
RORgt Inhibitors Suppress Th17 Cell Responses In Vivo
and Ameliorate EAE
We next examined the in vivo effects of the inhibitors on EAE,
in which the Th17 cell response plays a crucial role (Bettelli
et al., 2006). We induced EAE in C57BL/6 mice with MOG35–55
plus CFA immunization in conjunction with subcutaneousImmunity 40, 477–489, April 17, 2014 ª2014 Elsevier Inc. 479
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RORgt Inhibitors Regulate Th17 Cell Transcriptomeadministration of the inhibitors twice daily starting from day 0.
Compared to DMSO (control) treatment, treatment with all three
compounds delayed the onset of disease and substantially
reduced the severity of disease progression (Figure 1D). Con-
sistent with in vitro results, TMP778 treatment caused the most
pronounced effect on the disease phenotype (by severity and
day of onset). This treatment not only decreased the number of
mononuclear cells infiltrating the CNS but also most strongly
reduced the percentage of IL-17+ T cells (including IL-17+
IFN-g+ cells) in the CNS (Figure 1E). There was no significant
change in the percentage of IFN-g+IL-17 T cells in the CNS
among all groups, indicating that none of the inhibitors affects
Th1 responses. These data highlight TMP778 as the most potent
RORgt inhibitor among the three tested compounds. TMP778
strongly inhibited Th17 cell generation, reduced IL-17 produc-
tion from differentiated Th17 cells, and also dramatically amelio-
rated the progression of EAE.
RORgt Inhibitors Suppress the Th17 Cell Transcriptome
and Promote Alternate T Cell Subsets
Given the differential effects of the compounds on the inhibition
of Th17 cells and EAE development, we proceeded to analyze
the specific effects of each compound on gene transcription
by using RNA sequencing (RNA-seq). We measured the tran-
scriptome of WT Th17 cells treated with TMP778, TMP920,
digoxin, or DMSO and of RORgt-deficient Th17 cells treated
with DMSO. All samples were compared to DMSO-treated
WT Th17 cells. We clustered differentially expressed genes
(relative to those in vehicle-treated cells) by using K-means
clustering (Supplemental Experimental Procedures; Figure 2A;
Table S1) and observed five clusters, of which clusters 1 and 2
were the largest. Cluster 2 consisted of genes that were sup-
pressed after all perturbations (chemical or genetic) of RORgt;
these included many Th17-cell-specific genes (e.g., Il17a and
Il23r). Conversely, cluster 1 genes were induced after all pertur-
bations and included signature genes from other CD4+ T cell
lineages (e.g., Il4 and Tbx21, which encodes T-bet). Overall,
the most pronounced effect of RORgt inhibition was decreased
expression of Th17 cell signature genes, but there was also an
increase in the expression of genes that were preferentially ex-
pressed in other CD4+ T cell lineages (Figures 2A and S2A).
To further analyze this ‘‘balanced’’ pattern, we examined
the effect of each perturbation on sets of signature genes,
computationally derived for each CD4+ T cell lineage with the
use of published expression data (Wei et al., 2009) (Figure 2B;
Supplemental Information). Indeed, the RORgt inhibitors and
genetic ablation strongly suppressed the expression of Th17
cell signature genes (p < 104; Table S1) but also increased
the expression of signature genes from other CD4+ lineages,
most strongly for Th1 cell signature genes (e.g., Ifng and
Tbx21) and more mildly for Th2 cell genes (e.g., Il4) (Figures
2A and S2A; Table S1). Consistently, we saw significant over-
laps between the genes affected by each perturbation and
known targets of key TFs both in Th17 cells (e.g., BATF
and IRF4) and in other CD4+ T cells (e.g., STAT4, GATA3,
and Foxp3; Table S1; this analysis was based on publically
available data of TF-target interactions; see Supplemental
Experimental Procedures). Overall, these results suggest a
mode of competition or balance modulated by the transcrip-480 Immunity 40, 477–489, April 17, 2014 ª2014 Elsevier Inc.tional activity of RORgt (Bettelli et al., 2006; Yang et al.,
2011; Zhou et al., 2008).
To further confirm the potential medical relevance of these
observations, we verified the effects of TMP778 and TMP920
on Th17 cell signature genes in human cells (Supplemental Infor-
mation). We tested the effects on Th17 cell differentiation in vitro
from naive T cells and on differentiated Th17 cells restimulated
with IL-23 (by using different doses; Figures S2B–S2K).
We found that genes downregulated after TMP778 treatment
of CCR6+ memory T cells (i.e., a population enriched with Th17
cells) were overall upregulated in Th17 cells, and vice versa.
Furthermore, in a population depleted of Th17 cells (CCR6
cells), TMP778 had a very minor effect on transcription
(there were no differentially expressed genes with a fold cutoff
over 1.5), indicating that its effects are largely restricted to
Th17 cells.
TMP778 Most Closely Mimics the Effect of RORgt
Deletion
Although many transcriptional effects are common to all pertur-
bations (chemical inhibitors and Rorc ablation), there is also
substantial variation, suggesting different mechanisms of action
(Figure 2C). To estimate the overall extent to which the chemical
perturbations recapitulate genetic ablation of RORgt, we
computed the overlaps between their affected genes and the
genes affected by RORgt deficiency. Digoxin, followed by
TMP778 and TMP920, had the highest specificity rate
(a measure of the chance that a gene affected by a compound
is affected in the same way in RORgt deficiency). However,
TMP778, followed by TMP920 and digoxin, had the highest
sensitivity (a measure of the chance that a gene affected in
RORgt deficiency is affected in the same way by a compound).
Figure 2C shows the sensitivity and specificity of each com-
pound across a range of different fold changes in transcript
levels. A combined measure of specificity and sensitivity (har-
monic mean, or F-score) provides an overall estimate by which
TMP778 had the highest similarity to the effects of RORgt
deficiency, especially at genes that showed strong differential
expression (Figure 2C); this is in agreement with its more potent
effects on the Th17 cell phenotype in vitro and in vivo.
Identification of RORgt Binding Sites at the Th17 Cell
Genome
Some of the effects of RORgt inhibition (either by chemical
agents or by genetic manipulation) can be direct, whereas
others can reflect indirect events, either within Th17 cells
or due to changes in the balance of T cell populations. To better
distinguish these possibilities, we used chromatin immuno-
precipitation sequencing (ChIP-seq) to determine the direct
transcriptional targets of RORgt in Th17 cells (Figure 3A). Binding
events were selectively identified with two controls: an isotype
control immunoglobulin and the RORgt-specific antibody in
RORgt-deficient cells. Overall, our assay detected 2,257
high-confidence RORgt binding sites (Supplemental Experi-
mental Procedures). The accuracy of the detected binding sites
is further supported by a highly significant (p < 1010) DNA-
binding motif that was present in 58% of the sites (Figure 3B)
and that was nearly identical (p < 108) to the binding motif
of the nuclear receptor RORa. The DNA motif was also found,
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Figure 2. Effects of RORgt Inhibitors on the Th17 Cell Transcriptome
(A) Heatmap displaying the fold changes of genes (rows) in the various perturbations (columns). Displayed are only genes that were differentially expressed (fold
change > 1.5) in at least one condition. On the right is the differential expression of selected genes encoding transcriptional regulators (above) and cytokines or
cytokine receptors (below).
(B) Enrichment of the differentially expressed genes in gene signatures of different T cell subsets. The height of the bars indicates fold enrichment, and the color of
the bars indicates the percentage of overlap genes (i.e., differentially expressed genes belonging to the respective signature) that were overexpressed (from blue
to red).
(C) The overlap between the sets of genes affected by each compound and the sets of genes affected by RORgt deficiency was evaluated with an F-score: the
harmonic mean of their specificity (percentage of compound-affected genes affected by RORgt deficiency) and sensitivity (percentage of RORgt-deficiency-
affected genes affected by the compound). Results are presented for different fold-change cutoffs for calling differential expression in the compounds.
Immunity
RORgt Inhibitors Regulate Th17 Cell Transcriptomealbeit with considerably more noise, in anti-FLAG ChIP-seq with
the epitope-tagged exogenous RORgt in EL4 cells, a murine
lymphoma cell line (p = 2.6 3 103) (Supplemental Experimental
Procedures; Table S2). Interestingly, we also found additional
motifs, including SP1, AP-1, and STAT3, enriched (p < 105)in the RORgt binding sites. These results are in line with
previous findings of RORgt binding in proximity to STAT3,
IRF4, and BATF (Ciofani et al., 2012). Taken together, these
findings suggest that our ChIP-seq data reveal high-confidence
RORgt binding sites throughout the genome.Immunity 40, 477–489, April 17, 2014 ª2014 Elsevier Inc. 481
Figure 3. The Binding Landscape of RORgt in Th17 Cells
(A) RORgt binding at key Th17 cell gene loci.
(B) The RORgt binding motif (bottom) highly matches the known RORa binding motif (top).
(C) Overlap between the set of genes bound by RORgt and the genes affected by RORgt deficiency.
Immunity
RORgt Inhibitors Regulate Th17 Cell TranscriptomeRORgt Binds Genes Associated with Function of Th17
Cells and Other CD4+ T Cells, Acting as a Direct
Activator and Repressor, Respectively
There was a substantial overlap between the genes affected
by RORgt inhibition (chemical or genetic) and those directly
bound by it (Figure 3C; Table S1), and bound targets were also
highly enriched with both Th17 cell signature genes and
signature genes of other CD4+ T cell types (Figure 4A). On the
one hand, RORgt bound Th17 cell signature cytokine-
encoding genes (e.g., Il17a and Il7f), receptors for cytokines
that promote Th17 cell differentiation (e.g., Il23r), and key regu-
lators of T cell activation and Th17 cell differentiation (e.g., Irf4,
Junb, Ets1, and Nfatc2). On the other hand, it bound genes
such as that encoding the cytokine IL-2, which induces Th1 cells
and inhibits Th17 cell differentiation; inhibition of RORgt
also induced Il2 transcription from Th17 cells in our RNA-seq
experiments. This strongly supports our model of a ‘‘balanced’’
effect of RORgt on both Th17 cell signature genes (positively)
and signature genes of other CD4+ T cells (negatively) through
a direct mechanism. The fact that there was no discernable
bias toward upregulation or downregulation of bound genes
(chi square test, p > 0.1) suggests that RORgt can act both as
an activator at loci that promote Th17 cell differentiation and
as a repressor at other loci associated with other CD4+ T cell482 Immunity 40, 477–489, April 17, 2014 ª2014 Elsevier Inc.subsets. Interestingly, we found that target genes whose binding
sites contain the RORa binding motif tended to show stronger
overlap with the Th17 cell signature genes and the genes
affected by inhibition of RORgt (Figure S3). These results
might suggest that RORgt activity through cis-regulatory sites
that contain the RORa binding motif could be more relevant
to its role in Th17 cell differentiation. Notably, there was also
no discernable bias toward upregulation or downregulation
when we considered only binding targets associated with the
RORa motif.
RORgt Colocalizes with Other Master Regulators of
CD4+ T Cell Subsets
The chemical inhibitors (and genetic perturbation) of RORgt
led both to a decrease in the expression of Th17 cell signature
genes and to an increased expression of genes important for
the distinct function of other CD4+ T cell lineages. We hypo-
thesized that RORgt would co-occupy DNA elements with other
Th17 cell factors to coordinately activate genes important for
Th17 cell function and also bind to regulatory regions targeted
by TFs in other lineages to inhibit the expression of genes impor-
tant for those other lineages. To further explore how RORgt
participates in the control of genes important for Th17 cell func-
tion and signature genes from other CD4+ T cell lineages
AC
B
Figure 4. RORgt Selectively Targets Genes Associated with Th17 Cell Function and Signatures of Other CD4+ T Cells
(A) Enrichment (blue bars) and significance (brown bars) of RORgt target genes in signatures of different T cell subsets.
(B) Percentage of RORgt binding sites also occupied by other TFs in Th17 cells and other CD4+ T cell subsets.
(C) RORgt binding sites overlapped STAT3 (Yang et al., 2011), IRF4, and BATF in Th17 cells (Glasmacher et al., 2012) and with Foxp3 in iTreg cells at selected key
target genes.
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RORgt Inhibitors Regulate Th17 Cell Transcriptome(Figure 4A), we searched for other TFs that share target genes
with RORgt (Supplemental Experimental Procedures).
The individual binding sites and genes targeted by RORgt
significantly overlapped the specific binding sites and target
genes of key Th17 cell regulators (p < 103 for gene targets,
p < 1010 for individual binding sites; Table S2). In particular, a
significant portion of RORgt binding sites were also occupied
by STAT3 or STAT5 (40% of sites; e.g., Figures 4B and 4C)
(Yang et al., 2011) and/or by the pioneering factors IRF4 and
BATF (26% and 59% of peaks, respectively) (Glasmacher
et al., 2012). This is consistent with recent reports that cobinding
of RORgt with other transcriptional regulators promotes the
expression of genes that are crucial for Th17 cell function (Cio-
fani et al., 2012). Notably, Rorc was targeted by some of these
key factors, including IRF4 and RORgt itself (Figure 4C), forming
feed-forward, feedback, and autoregulatory loops. Thus, RORgtis a central node in a densely interconnected cooperative
network for activating Th17 cell genes.
Interestingly, there was also a significant overlap between
RORgt binding sites and those of factors controlling other
T cell subsets, consistent with a model of directly opposing tran-
scriptional effects. For example, comparing RORgt binding sites
to GATA3 binding sites in Th2 cells (Wei et al., 2011), we discov-
ered a statistically significant overlap (>6.5% of binding sites,
>20-fold enrichment), suggesting that divergent transcriptional
effects at shared target genes might be a mode of action by
which RORgt promotes the Th17 cell state.
The reciprocal relationship between developmental pathways
controlling the differentiation of RORgt+ Th17 cells and Foxp3+
Treg cells (Bettelli et al., 2006) raises the hypothesis that similar
(or stronger) overlaps might exist with the Treg cell TF Foxp3.
Because ChIP-seq data for Foxp3 in induced Treg (iTreg) cellsImmunity 40, 477–489, April 17, 2014 ª2014 Elsevier Inc. 483
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of Foxp3 in iTreg cells and compared the results to those of
the RORgt binding sites in Th17 cells. We found that >10% of
the binding sites were shared between the two factors
(p < 1010, 28-fold enrichment) and thus covered many
key genes. For example, the RORgt and Foxp3 overlapping
regions included Il17 and the promoters and putative enhancers
of genes that characterize either Th17 or iTreg cells, including
Il23r, Ctla4, Il2, Il21, Il2ra, Il7r, Ptpn22, and mir-155 (Figures 4B
and 4C). The findings strongly suggest that RORgt and Foxp3
promote reciprocal developmental pathways by acting at a
shared set of genomic regions in Th17 and Treg cells, respec-
tively. Furthermore, these findings lend insight into the obser-
vation that a subset of Treg cell signature genes tend to be
expressed at higher levels in Th17 cells treatedwith RORgt inhib-
itors (Figure 2B).
Distinct Effects of Inhibitors on RORgt-DNA Interactions
Although small-molecule inhibition largely recapitulated the
transcriptional effect of genetic ablation of RORgt, including
the effect on its direct targets (Figure 2B), this does not clarify
the mechanism by which the compounds disrupt the regulatory
circuitry. In principal, the compounds could either reduce the
occupancy of RORgt at DNA regulatory elements or disrupt
the transcriptional effects of RORgt without removing its DNA
binding by affecting protein-protein interactions and suppress-
ing RORgt-dependent gene transcription. To differentiate be-
tween the two models, we performed ChIP-seq analysis for
RORgt in Th17 cells treated with each compound, or vehicle
control, and in RORgt-deficient cells.
Strikingly, TMP920 significantly reduced the occupancy of
RORgt at the majority of its target genomic elements (decreased
ChIP signal in 77% of sites; left-tailed t test, p < 1 3 1010,
comparing fold changes in untreated Th17 cells to those in
DMSO-treated Th17 cells), whereas RORgt binding to the
genome was largely preserved in cells treated with TMP778
(lower ChIP signal in 55% of sites, p > 0.5; Figures 5A, S4, and
S5). The effect on RORgt binding in digoxin-treated cells was
intermediate, but much of the RORgt binding was preserved in
these cells as well. To rule out that binding differences were
secondary to transcriptional inhibition of Rorc, we confirmed
that, at the concentrations used here, the respective RORgt
inhibitors did not significantly inhibit the mRNA expression of
Rorc (Figure S2A). These findings suggest that the chemical
inhibitors affect the transcriptional network by different mecha-
nisms. In particular, TMP778, the most potent compound, which
most closely recapitulated the transcriptional effects of RORgt
deficiency, had the least pronounced effect on RORgt DNA
binding, as observed by ChIP-seq analysis.
To confirm these findings and explore them further, we
performed ChIP-PCR analysis for a select set of loci that showed
variable RORgt binding depending on chemical treatment. At
the panel of loci we tested, we confirmed the observation that
much of RORgt binding was preserved in cells treated with
TMP778 and partly preserved in cells treated with digoxin (Fig-
ures 5B and S4). At multiple loci, we observed a dose-related
effect on RORgt binding with each of the compounds. However,
at the concentrations where we observed potent transcriptional
and phenotypic effects with TMP778, RORgt binding to DNA484 Immunity 40, 477–489, April 17, 2014 ª2014 Elsevier Inc.was preserved at most of its target regions, including multiple
loci within the Il17a and Il17f genomic regions (Figure 5B).
In addition to examining loss of RORgt binding due to chemi-
cal treatment, we also examined whether any RORgt DNA-
binding interactions were further enhanced or stabilized as a
result of the chemicals. ChIP-seq experiments have significant
noise and well-known potential for false-negative results at any
particular locus. Nonetheless, we employed a stringent compu-
tational approach (by using a noise model based on variation
between RORgt binding patterns observed in untreated cells
and vehicle-treated cells) to identify candidate loci where RORgt
DNA occupancy appeared to be stabilized by chemical treat-
ment. Remarkably, this approach revealed that treatment with
TMP778 led to RORgt occupancy of 179 binding sites not
observed previously in our data in Th17 cells (8.2% of peaks
observed with TMP778 with the use of several criteria for peak
filtering; see Supplemental Experimental Procedures; Table
S3). Notable among them was the TMP778-dependent binding
of RORgt to Gata3, encoding the master TF for Th2 cell differen-
tiation. RORgt binding to two intronic regions within Gata3 was
only observed in cells treated with TMP778; one of these regions
was further confirmed with statistical significance with ChIP-
PCR (Figure 5C). Indeed, the RNA-seq data revealed that
Gata3 was expressed at higher levels in cells treated with
TMP778 (Figure 2A), and intracellular-staining data confirmed
increased expression of GATA3 in cells treated with TMP778
(Figure S6A). Furthermore, genes bound by GATA3 (Wei et al.,
2011) were also upregulated after TMP778 treatment compared
to vehicle treatment (p < 1010). Interestingly, Gata3 was also
occupied by the Th17 cell pioneering TFs IRF4 and BATF in
Th17 cells (Glasmacher et al., 2012) and by the Treg cell TF
Foxp3 in iTreg cells. More generally, we found that a substantial
percentage of all new TMP778-dependent binding sites were
similarly occupied by IRF4 and BATF in Th17 cells (14.5%
and 65%, respectively), consistent with the published model
suggesting that these pioneering factors promote chromatin
accessibility (Ciofani et al., 2012). These data suggest that the
chemical inhibitors, in addition to inhibiting the Th17 cell tran-
scriptional program, might also promote stabilization of RORgt
to unique binding sites to induce transcriptional modules spe-
cific to each inhibitor.
Orally Available Compound GSK805 Inhibits the RORgt-
Dependent Transcriptional Network to Treat Th17-Cell-
Mediated Autoimmunity
Although two inhibitors presented here potently inhibit Th17 cell
responses, especially TMP778, their potential clinical usage is
limited by their required subcutaneous administration. By further
screening with a FRET-based assay, we obtained another
RORgt inhibitor, GSK805 (Figure 6A). At a dose of 0.5 mM, com-
pound GSK805 showed inhibition of IL-17 production compara-
ble to that of TMP778 at 2.5 mM during Th17 cell differentiation
(Figure 6B), suggesting that GSK805 is even more potent than
TMP778 at inhibiting Th17 cell responses. Strikingly, when orally
administrated into the hosts at the time of disease induction, the
compound GSK805 could efficiently ameliorate the severity of
EAE (Figure 6C). Analysis of CNS samples after 14 days of
GSK805 treatment revealed that the treatment strongly inhibited
Th17 cell responses (i.e., reduced both IFN-gIL-17+ and
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Figure 5. Distinct Effects of Inhibitors on RORgt-DNA Interactions
(A) RORgt binding near transcription start sites (TSSs). Every line depicts the 6 kb region around a TSS (center) in 300 bpwindows. Shown are the 1,544 TSSs that
contained a binding peak (p < 108; Experimental Procedures) in at least one condition (compounds, DMSO, untreated Th17 cells) and did not contain any signal
(Z score > 0.1) in the control (RORgt-deficient) cells. Color intensity is proportional to the number of reads mapped to each window (reads were normalized
separately for each condition with the use of Z scores).
(B and C) The effects of RORgt inhibitors on RORgt occupancy at Il17a and Il17f (B) andGata3 (C) were validated by ChIP-PCR. Naive CD4+ T cells were cultured
under Th17-cell-polarizing conditions in the presence of the indicated doses of RORgt inhibitors. After 96 hr, ChIP was performed with anti-RORgt, and real-time
PCR analysis followed. Th17 cells for ChIP-seq were cultured in the presence of 2.5 mM TMP778, 10 mM TMP920, 10 mM digoxin, or DMSO for 96 hr. The RORgt
binding sites in Il17a, Il17f, and Gata3 are as indicated in the ChIP-seq binding tracks. ChIP-PCR was used to confirm binding at selected sites (shown below
ChIP-seq tracks), and the RORgt occupancy (percentage of input) is shown as ‘‘enrichment.’’ Data are representative of two experiments. Error bars represent the
mean ± SD. The TMP778-induced RORgt binding site in Gata3 in Th17 cells overlapped STAT3, IRF4, and BATF in Th17 cells and Foxp3 in iTreg cells.
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frequency of TNF-a+ T cells (Figures 6D and S6B).
We then determined the global effects of GSK805 on tran-
scription in Th17 cells by using a cost-efficient RNA-seq proto-
col. We saw an overall high degree of similarity between the
effects of GSK805 and those of the other compounds (r2 > 0.5,
p < 1 3 1010; Figure 6E). ChIP-PCR data suggest that similarto TMP778, compound GSK805 did not affect RORgt binding
to DNA in many genes and also induced RORgt binding to
Gata3 and was associated with increased GATA3 expression
(Figures S6A and S6C).
Taken together, these results indicate that GSK805, an orally
administered compound, inhibits RORgt transcriptional effects
and Th17 cell function through mechanisms overlapping thoseImmunity 40, 477–489, April 17, 2014 ª2014 Elsevier Inc. 485
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Figure 6. Effects of RORgt Inhibitor GSK805
on Th17Cells and Th17-Cell-Mediated Auto-
immune Diseases
(A) Chemical structure of GSK805.
(B) Naive CD4+ T cells were activated under Th17-
cell-polarizing conditions in the presence of
GSK805 (0.5 mM), TMP778 (2.5 mM), or DMSO.
After 4 days, IL-17 and IFN-g production was
measured by intracellular cytokine staining. Data
are representative of three experiments.
(C) C57BL/6 mice were immunized with MOG35–55
plus CFA, and RORgt inhibitor GSK805 (10 mg/kg)
was orally given daily starting from day 0. Mice
(n = 8) were evaluated daily for signs of EAE. Error
bars represent the mean ± SD. *p < 0.01 by
repeated ANOVA test.
(D) C57BL/6 mice were induced for EAE and
treated with GSK805 (30 mg/kg). On day 14, CNS-
infiltrating cells were isolated and measured for IL-
17 and IFN-g production by intracellular staining.
Error bars represent the mean ± SD. *p < 0.001.
(E) Comparison of gene expression under the
various perturbations (indicated in the legend)
with WT DMSO. The figure depicts the average
fold change of the genes in clusters 1–5 from
Figure 2A.
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suggest that it could be a promising lead compound for the treat-
ment of Th17-cell-mediated diseases.
Discovery of a Densely Interconnected Regulatory
Network Downstream of RORgt
Our data collectively reveal that RORgt plays a central role in a
transcriptional network shaping CD4+ T cell identity. We dis-
covered that the genomic binding sites of RORgt neighbor the
binding sites of other key TFs in Th17 cells and TFs in other
T cell subsets, as assessed by DNA motif analysis and ChIP-
seq. By computing the overlaps between the RORgt-bound
genes and the targets of other TFs, we found many cases of
substantially overlapping TFs, including STAT4, GATA3, and
Foxp3. The transcriptional data from RORgt-deficient cells pro-
vide further support: the affected genes also overlapped the
targets of a similar set of TFs (including STAT4, GATA3, and
Foxp3). Together, these results provide functional support for
the RORgt-centric network presented in Figure 7 and place
RORgt as a regulatory hub that not only affects Th17 cell signa-
ture genes but can also directly or indirectly affect the regulatory
program of other T cell subsets. These data suggest a tran-
scriptional regulatory network where an important set of genes,
encoding proteins with roles in T cell differentiation and effector
function, are coordinately regulated by a core set of master TFs
that control CD4+ T cell lineage differentiation. These TFs could486 Immunity 40, 477–489, April 17, 2014 ª2014 Elsevier Inc.be acting cooperatively to enforce
appropriate gene-expression programs,
and pharmaceutical compounds could
disrupt necessary protein-protein inter-
actions and thus modulate T cell differen-
tiation. Indeed, we highlight the potentmodulation of this network by compounds that inhibit RORgt-
dependent Th17 cell differentiation and affect the network in a
manner similar to genetic ablation of RORgt.
DISCUSSION
We report here three small-molecule inhibitors of RORgt, a
nuclear receptor that is essential for Th17 cell development.
We provide in vitro and in vivo evidence that these molecules
repress the development of Th17 cells and have a substantial
effect in ameliorating the autoimmune disease EAE, a murine
model of multiple sclerosis. Strikingly, not only is the compound
GSK805 more potent than other compounds at inhibiting Th17
cell responses, but it can also be orally administrated for
treatment of Th17-cell-mediated autoimmune diseases, such
as EAE. To better characterize these inhibitors, we analyzed
their function within the context of the transcriptional network
that is controlled by RORgt in Th17 cells. We discovered that
RORgt directly controls the expression of a set of genes that
lie at the core of Th17 cell identity and also contributes to the
repression of signature genes of other CD4+ T cell lineages.
The chemical molecules largely recapitulate the transcriptional
effects of genetic ablation of RORgt on these target genes.
Furthermore, we used ChIP-seq to identify the DNA regulatory
elements directly occupied by RORgt and to assess the effects
of the small molecules on DNA binding. In addition to providing
A B
Figure 7. RORgt Is a Regulatory Hub in a
Densely Interconnected Network of CD4+ T
Cell Regulation
Depicted are TFs that shared a significant (p <
103) number of common targets with RORgt
(inner circle) and that shared a target subset that
was also differentially expressed under perturba-
tion of RORgt (outer circle; shown are only genes
associated with immune response; see Tables S1
and S2 for the complete lists). Edges indicate TF
binding in a target gene. Node colors reflect the
modulation of mRNA levels in RORgt-deficient
cells (A) or under TMP778 treatment (B).
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in the treatment of human autoimmune disease, these studies
also provide a unique paradigm for combining drug-discovery
efforts with mechanistic, genome-wide analysis of transcrip-
tional regulation in defined primary T cells that mediate tissue
inflammation.
Importantly, the RORgt network targeted by the identified
compounds includes master regulators in other CD4+ T cell
populations that are transcriptionally affected by RORgt pertur-
bation, are bound by RORgt, or share target genes with RORgt.
These findings offer insight into our observation that perturbation
(by either genetic ablation or targeting compounds) of RORgt not
only inhibits the expression of Th17 cell signature genes but also
contributes to the activation of signature genes from other T cell
lineages. Specifically, we have demonstrated that the master
Treg cell TF Foxp3 binds in iTreg cells a significant percentage
of the regulatory elements occupied by RORgt in Th17 cells.
This is consistent with a model where STAT3, which promotes
Th17 cell differentiation, and STAT5, which promotes Treg cell
development, might compete for genomic binding sites (Yang
et al., 2011) where RORgt binds. Our discovery of the overlap
between RORgt and Foxp3 further suggests that the reciprocal
development of Th17 and Treg cells is driven, at least in part,
by differential regulation of a key set of common target genes.
This appears to be a general feature of the regulatory circuitry
controlling the closely related CD4+ T cell lineages. For instance,
T-bet and GATA3 occupy a shared set of promoter elements to
regulate differentiation toward Th1 and Th2 cell lineages,
respectively (Jenner et al., 2009).
One of the major limitations in developing therapeutic agents
is the challenge of identifying compounds that affect a specific
biologic target and downstream network with minimal off-target
effects. In the studies described here, the biologic target of
interest was a transcriptional regulator. Here, we have estab-
lished a proof of principle that systematic, quantitative studies
of the DNA binding and transcriptome of cells treated with theImmunity 40, 477–4identified compounds can provide insight
into their biologic effect. The ideal is to
discover a compound that would mirror
all of the RORgt-dependent transcrip-
tional effects (which we describe as the
drug’s sensitivity in hitting the desire tran-
scriptional targets) with no collateral
effect on genes not controlled by RORgt(which we measure as the drug’s specificity). Using the genomic
analysis described here, it might even be possible to selectively
inhibit proinflammatory modules activated by RORgt while
leaving other modules activated by RORgt intact. We used an
F-score to integrate the sensitivity and specificity of the studies’
compounds. With this index, TMP778 performed better than
digoxin and TMP920, which is consistent with its potent role in
abrogating the in vivo and in vitro differentiation of Th17 cells.
Furthermore, specific transcriptional modules that are selec-
tively induced by a compound of interest, such as the GATA3-
dependent module induced by TMP778 and GSK805, might
ultimately provide insights into unexpected effects of candidate
therapeutics. This systematic approach is likely to prove useful
as a growing number of compounds targeting transcriptional
regulators become available as potential therapeutic agents for
a wide range of human diseases.
We further characterized the molecular mechanism of the
identified compounds by using ChIP-seq. This approach un-
expectedly revealed significant divergence in the mechanisms
by which the various compounds affect the transcriptional
network downstream of RORgt. Notably, the compound with
the highest F-score, as discussed above, had the least profound
effect on RORgt DNA binding. This finding underscores that
occupancy of the genome at key regulatory elements is not
sufficient for master regulators to exert their transcriptional
effects. TFs, including nuclear receptors such as RORgt, depend
on contact with coregulatory molecules to control gene expres-
sion. All three compounds described here—TMP778, TMP920,
and GSK805—were identified as inverse agonists that interact
physically with the putative ligand-binding domain of RORgt.
Through its interaction with this domain, TMP920 appears to
also disrupt RORgt binding to DNA, whereas TMP778 and
GSK805 interactions with RORgt ligand binding domain exert
less pronounced effects on DNA binding. This raises the possi-
bility that these compounds exert their pharmacological effects
by disrupting RORgt interaction with a currently unidentified89, April 17, 2014 ª2014 Elsevier Inc. 487
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gulators or the RNA-polymerase machinery independently of
whether or not DNA binding is disrupted.
In summary, we have identified compounds that antagonize
the transcriptional effects of RORgt. These compounds block
Th17 cell differentiation and help to limit Th17-cell-mediated
diseases. Furthermore, we have gained insight into the mecha-
nism of these compounds by examining in detail the tran-
scriptional regulatory circuitry of Th17 cells. The network model
provided here highlights the transcriptional effects of the com-
pounds on genes that lie at the core of Th17 cell function. In
turn, these data also serve as a valuable resource for those inter-
ested in studying genes under direct transcriptional control of
RORgt in Th17 cells, including genes encoding effector mole-
cules, cell-signaling components, transcriptional regulators,
cytokines, and cell-surface molecules. These studies represent
a unique approach of combining drug-discovery efforts and
systematic genomic investigations of transcriptional regulation,
which can predict specific, off-target and new-target effects
induced by a drug candidate. This approach can be very instruc-
tive in selecting lead candidates and has considerable potential
to aid in drug discovery and the identification of new effective
therapeutic agents for human diseases.
EXPERIMENTAL PROCEDURES
Mice and Reagents
C57BL/6, RORgtGFP, and Rorcfl/fl mice were purchased from The Jackson
Laboratory. Rorcfl/fl mice were bred with CD4-Cre transgenic mice for obtain-
ing T-cell-specific RORg-RORgt-null mice. Mice were maintained and all
animal experiments were done according to the animal protocol guidelines
of Harvard Medical School and GlaxoSmithKline (GSK). MOG35–55 was syn-
thesized by Quality Controlled Biochemicals. Digoxin and DMSO were
purchased from Sigma-Aldrich. TMP778 and TMP920 were synthesized by
Tempero Pharmaceuticals, and GSK805 was synthesized by GSK. All fluores-
cence-conjugated Abs were obtained from Biolegend, eBioscience, and BD
Biosciences. All cytokines were purchased from eBioscience and R&D
Systems.
Naive CD4+ T Cell Isolation and Stimulation
CD4+CD62LhiCD25 naive CD4+ T cells were purified by fluorescence-
activated cell sorting after a magnetic-activated-cell-sorting bead isolation
of CD4+ cells as previously described (Xiao et al., 2008). Naive CD4+ cells
were activated with plate-bound anti-CD3 (2 mg/ml) and anti-CD28 (2 mg/ml).
For Th17 cell differentiation, cultures were supplemented with IL-6
(20 ng/ml) plus TGF-b1 (1 ng/ml), and IL-23 (10 ng/ml) was added after
48 hr. RORgt inhibitors or vehicle control DMSO was also included in the
cultures or as indicated in the figure legends. After 96 hr, cells were collected
for further experiments.
EAE Induction and Treatment with TMP778, TMP920, and Digoxin
Female C57BL/6 mice (8–12 weeks old) were immunized subcutaneously in
the flanks with an emulsion containing MOG35–55 (100 mg/mouse) and
M. tuberculosis H37Ra extract (3 mg/ml, Difco Laboratories) in CFA (100 ml/
mouse). Pertussis toxin (100 ng/mouse, List Biological Laboratories) was
administered intraperitoneally on days 0 and 2. RORgt inhibitor (TMP778,
200 mg per injection; TMP920, 500 mg per injection; digoxin, 50 mg per injection
[>100 mg caused mouse death]) were subcutaneously injected twice daily
throughout the period of the experiments. Mice were monitored and assigned
grades for clinical signs of EAE as previously described (Xiao et al., 2008).
Flow Cytometry
For intracellular cytokine staining, cells were stimulated in culture medium
containing phorbol 12-myristate 13-acetate (30 ng/ml, Sigma-Aldrich), iono-488 Immunity 40, 477–489, April 17, 2014 ª2014 Elsevier Inc.mycin (500 ng/ml, Sigma-Aldrich), and GolgiStop (1 ml/ml, BD Biosciences)
in a cell incubator with 10% CO2 at 37
C for 4 hr. After surface markers
were stained, cells were fixed and permeabilized with Cytofix/Cytoperm and
Perm/Wash buffer (BD Biosciences) according to the manufacturer’s instruc-
tions. Then, cells were stained with fluorescence-conjugated cytokine Abs
at 25C for 30 min before analysis. 7-aminoactinomycin D (BD Biosciences)
was also included to gate out the dead cells. All data were collected on a
FACSCalibur or an LSR II (BD Biosciences) and analyzed with FlowJo software
(TreeStar).
ChIP-Seq and RNA-Seq
Antibodies used for ChIP were anti-RORgt (Clone AFKJS-9, eBioscience),
anti-Foxp3 (Zheng et al., 2007), anti-FLAG (clone M2), and IgG control.
Purified ChIP DNA was used for preparing ChIP-seq libraries with the Illumina
TruSeq DNA Sample Preparation Kit v.2. Total RNA was used for preparing
RNA-seq libraries with the Illumina TruSeq RNA Sample Preparation Kit.
Libraries were sequenced with single-end 36 bp reads on an Illumina GAII.
Sequencing data were analyzed as described in the Supplemental Experi-
mental Procedures.
Detailed experimental procedures can be found in the Supplemental Exper-
imental Procedures.ACCESSION NUMBERS
The ChIP-seq and RNA-seq data are available in the Gene Expression
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/gds) under the acces-
sion number GSE56020.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, Supplemental Experimental
Procedures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2014.04.004.
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